Table 3 Treatment, Follow-Up, and Prognosis of Recently Reported Xp11.2 Translocation Renal Cell Carcinomas in Patients Aged 16 or Older
| Â | Â | Â | Treatment | Pattern of Progression | Â | Â | ||
|---|---|---|---|---|---|---|---|---|
Source, Year | Pts, No. | Age, y/Sex | Primary Treatment | Additional Treatment | Local Recurrence | Metastases | Follow-Up Time, y | Outcome |
Dal Cin et al, 1998 [10] | 1 | 53/F | RN | Resection of metastases | None | Lung, bone, liver, adrenal, retroperitoneal LNs | 31 | NS |
Salles and Soto, 2005 [11] | 1 | 58/F | RN | None | None | Renal hilar LNs | 0.5 | FOD |
Mansouri et al, 2006 [12] | 1 | 16/F | RN | Resection of metastases, ChemoRx, IFN-α, IL-2 | Yes | Lung, bone, adrenal, lumbar-aortic LNs | NS | NS |
Schinstine et al, 2006 [13] | 1 | 57/F | RN | Resection of metastases | None | Lung | 1 | NS |
Meyer et al, 2007 [14] | 5 | 32.6 (mean)/5M | 4 RN; 1 renal Bx | Resection of metastases, ChemoRx, XRT, IL-2, investigational agents | Yes | Lung, bone, liver, brain, mediastinal LNs | 1.5 (mean) | 2 DOD |
Rais-Bahrami et al, 2007 [15] | 1 | 23/M | RN | Resection of metastases, ChemoRx, investigational agents | None | Lung, liver, retroperitoneal, supraclavicular, cervical and mediastinal LNs | 17 | DOD |
Suzigan et al, 2007 [16] | 1 | 17/F | PN | None | None | None | 0.33 | FOD |
Argani et al, 2007 [17] | 28 | 22–68 (range)/22F, 6M | NS | NS | NS | 5 hematogenous metastases | NS | 2 DOD |
Armah and Parwani, 2008 [18] | 1 | 33/M | RN | Resection of metastases, ChemoRx, XRT, IFN-α, IL-2 | None | Lung, liver, bone, brain, mediastinal LNs | 0.58 | DOD |
Camparo et al, 2008 [19] | 31 | 24.6 (mean)/18F, 13M | 30 RN; 1 renal Bx | Resection of metastases, ChemoRx, XRT, IFN-α, IL-2, investigational agents | NS | Lung, liver, bone, LNs | 0.5–7.67 (range) | 5 DOD |
Wu et al, 2008 [9] | 3 | 17–20 (range)/1F, 2M | 3RN | Resection of metastases, investigational agents | Yes | Retroperitoneal LNs | 1.7–3.4 (range) | 1 DOD |
Gellar et al, 2008 [20] | 4 | 16–17 (range)/3F, 1M | 4RN | ChemoRx, IFN-α, IL-2, investigational agents | None | Lung, liver | 1.17–15.42 (range) | 1 DOD |
Hintzy et al, 2008 [21] | 6 | 28–42 (range)/4F, 2M | NS | NS | NS | 3 hematogenous metastases | 2.67 (mean) | 1 DOD |
Komai et al, 2009 [22] | 6 | 24–59 (range)/2F, 4M | 6RN | Resection of metastases, IFN-α, IL-2 | None | Lung, liver, LNs | 0.75–11 (range) | 2 DOD |
Bovio et al, 2009 [23] | 1 | 20/F | RN | NS | None | Placenta, bone, retroperitoneal LNs | 2 | NS |
Koie et al, 2009 [24] | 1 | 28/M | RN | Resection of metastases, IFN-α, IL-2 | Yes | Lung, liver, adrenal, spleen, pancreas, psoas muscle, mesentery, descending colon, retroperitoneal LNs | 2 | DOD |